These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37956980)

  • 1. Risk Factors Analysis of Severe Liver Injury Induced by Statins.
    Su FY; Li WH; Zhao XD; Han Q; Xu X; Geng T
    Horm Metab Res; 2024 Jun; 56(6):419-423. PubMed ID: 37956980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin-induced liver injury in an area endemic for hepatitis B virus infection: risk factors and outcome analysis.
    Wang LY; Huang YS; Perng CL; Huang B; Lin HC
    Br J Clin Pharmacol; 2016 Sep; 82(3):823-30. PubMed ID: 27197051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study.
    Chang CH; Chang YC; Lee YC; Liu YC; Chuang LM; Lin JW
    J Gastroenterol Hepatol; 2015 Jan; 30(1):155-62. PubMed ID: 25041076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin-induced lung injury: diagnostic clue and outcome.
    Huang LK; Tsai MJ; Tsai HC; Chao HS; Lin FC; Chang SC
    Postgrad Med J; 2013 Jan; 89(1047):14-9. PubMed ID: 23043128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins and the risk of liver injury: a population-based case-control study.
    Chen GL; Hsiao FY; Dong YH; Shen LJ; Wu FL
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):719-25. PubMed ID: 24829162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin-associated ocular disorders: the FDA and ADRAC data.
    Mizranita V; Pratisto EH
    Int J Clin Pharm; 2015 Oct; 37(5):844-50. PubMed ID: 25939673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced liver injury associated with statins.
    Russo MW; Scobey M; Bonkovsky HL
    Semin Liver Dis; 2009 Nov; 29(4):412-22. PubMed ID: 19826975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.
    García Rodríguez LA; Herings R; Johansson S
    Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1218-24. PubMed ID: 20922707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries.
    Chaipichit N; Krska J; Pratipanawatr T; Jarernsiripornkul N
    Int J Clin Pharm; 2015 Apr; 37(2):355-64. PubMed ID: 25630895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect?
    Onfiani G; Nascimbeni F; Carubbi F
    J Basic Clin Physiol Pharmacol; 2021 Apr; 32(6):1151-1155. PubMed ID: 33882199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.
    Russo MW; Hoofnagle JH; Gu J; Fontana RJ; Barnhart H; Kleiner DE; Chalasani N; Bonkovsky HL
    Hepatology; 2014 Aug; 60(2):679-86. PubMed ID: 24700436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
    Dormuth CR; Hemmelgarn BR; Paterson JM; James MT; Teare GF; Raymond CB; Lafrance JP; Levy A; Garg AX; Ernst P;
    BMJ; 2013 Mar; 346():f880. PubMed ID: 23511950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.
    Conforti A; Magro L; Moretti U; Scotto S; Motola D; Salvo F; Ros B; Leone R
    Drug Saf; 2006; 29(12):1163-72. PubMed ID: 17147462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the adverse risk of statin treatment: an independent and external validation of Qstatin risk scores in the UK.
    Collins GS; Altman DG
    Heart; 2012 Jul; 98(14):1091-7. PubMed ID: 22689714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Statin-related drug-induced liver injury].
    Li XY; Zhong W; Mao YM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):659-663. PubMed ID: 37400395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualising the risks of statins in men and women in England and Wales: population-based cohort study.
    Hippisley-Cox J; Coupland C
    Heart; 2010 Jun; 96(12):939-47. PubMed ID: 20489220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry.
    Perdices EV; Medina-Cáliz I; Hernando S; Ortega A; Martín-Ocaña F; Navarro JM; Peláez G; Castiella A; Hallal H; Romero-Gómez M; González-Jiménez A; Robles-Díaz M; Lucena MI; Andrade RJ
    Rev Esp Enferm Dig; 2014 Apr; 106(4):246-54. PubMed ID: 25075655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg.
    Stein B; Ward T; Hale G; Lyver E
    Ann Pharmacother; 2020 May; 54(5):405-413. PubMed ID: 31718234
    [No Abstract]   [Full Text] [Related]  

  • 19. Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA): A randomized clinical trial.
    Lv X; Liu X; Peng Y; Li W; Wang J; Chen X; Lei J; Tang C; Luo S; Mai W; Cai Y; Fan Q; Liu C; Zhang L
    J Stroke Cerebrovasc Dis; 2024 May; 33(5):107647. PubMed ID: 38431112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of short-term dual antiplatelet therapy combined with intensive rosuvastatin in acute ischemic stroke.
    Deng T; He W; Yao X; Chen J; Liu X; Liu L; Zhang T; Lu H
    Clinics (Sao Paulo); 2023; 78():100171. PubMed ID: 36738644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.